A synthesis published this spring pulled together the strongest strands of the microplastics evidence and laid out both what has been established and what has not. Two findings anchor it. Brain tissue samples carry microplastic concentrations far higher than liver or kidney, by a factor the authors put between seven and thirty. And in patients who had plaque surgically removed from a carotid artery, those whose plaque contained detectable plastic particles had roughly four times the combined risk of heart attack, stroke or death over the following months.

Those are serious numbers from serious groups. They are also, at this stage, associations in small clinical populations, and the same authors are explicit that the measurement tools needed to settle the question do not yet exist.

From the Lab to the Ledger

Microplastics are fragments smaller than five millimeters, and the ones that matter biologically are far smaller still: nanoplastics measured in billionths of a meter, small enough that animal studies show them crossing the blood-brain barrier. They come from packaging, textiles, tires, water systems and the breakdown of larger plastic in the environment, which is why exposure is not something an individual opts into.

The carotid finding is the most consequential and also the most easily misread. Plaque containing plastic particles marked patients at much higher risk of a subsequent cardiovascular event. It does not follow that the plastic caused the event. Plaque that accumulates foreign particles may simply be more inflamed, more disorganized, or older, and inflammation is already the mechanism that makes plaque dangerous. The particles could be a cause, an accelerant, or a marker of a plaque that was going to rupture anyway. The authors of the synthesis name that uncertainty directly, describing the open question as whether microplastics are passengers, accelerators or contributors.

The brain finding has a similar structure. Concentrations were measured in tissue collected over several years, with the highest levels in samples from people who had dementia. That is exactly the pattern you would expect if plastics contributed to neurodegeneration, and also the pattern you would expect if a damaged, inflamed brain with a compromised barrier simply accumulates and retains more of what circulates. Autopsy tissue cannot distinguish between those.

What makes this hard to resolve is unglamorous: measurement. There is no standardized, validated method for quantifying specific polymers in human tissue at these sizes, which means results are difficult to compare between laboratories and impossible to use as an endpoint in a trial. Until that infrastructure exists, nobody can run the study that would answer the question, because nobody can reliably measure whether an intervention lowered anyone's burden.

Bio-Pipeline Ledger

Presence of microplastics in human tissue including blood, placenta, plaque and brain: established across multiple independent laboratories. This part is not in dispute.

Causal harm from microplastics in humans: not established. The strongest human data are associations in small surgical and autopsy cohorts, with plausible alternative explanations.

Animal evidence of nanoplastic transport across the blood-brain barrier and of inflammatory effects: real, consistent, and at exposure levels that do not straightforwardly translate to human daily life.

Standardized measurement of polymer-specific concentrations in human tissue: not yet available. This is the bottleneck holding back every downstream question, including any test claiming to measure your personal burden.

Reducing exposure through practical substitutions, such as not heating food in plastic, filtering drinking water, and reducing single-use packaging: low cost, low risk, and unproven as a health intervention because the trial cannot currently be run. Reasonable on precaution, not on evidence.

Detox protocols, chelation, or supplements sold to remove microplastics: no evidence of any kind. There is no validated way to measure the burden, which makes a claim to lower it unfalsifiable by design.

The Clinical Reality Check

The verified position is uncomfortable but clear. Microplastics are in human tissue, including tissue nobody expected them to reach, and there are associations with cardiovascular events and with dementia that are strong enough to justify serious research funding. There is no evidence establishing that they cause disease in humans, and no method exists to measure an individual's exposure meaningfully.

What is being oversold is certainty in both directions. Dismissing this as alarmism ignores real findings from serious laboratories, and treating it as settled science ignores what the researchers themselves say about the state of the evidence. Anyone selling a product to fix it is selling a solution to a problem that cannot currently be measured.

The proportionate response is to make the cheap substitutions that reduce exposure without reorganizing your life around them, and to keep attention on the risks that are established, measurable and modifiable. Blood pressure and LDL cholesterol still explain far more of your cardiovascular risk than anything in this research, and both can be measured this week.